Activating mutation of epidermal growth factor receptor (EGFR) is correlated with malignant lung tumor. In our study, we demonstrated that recombinant LZ-8 (rLZ-8), a medicinal mushroom Ganoderma lucidum protein, induced cell cycle arrest and apoptosis by downregulating the expression of wild-type and mutated EGFR and inhibiting EGFR downstream effectors, AKT and ERK1/2 in lung cancer cells. We showed that rLZ-8 effectively inhibited lung cancer progression and suppressed EGFR expression of lung tumor lesions in mouse model. Functional studies revealed that rLZ-8 reduced the amount of EGFR in cell membranes by altering EGFR localization to enhance the EGF-induced degradation of EGFR. Mechanistically, we demonstrated that rLZ-8 bound to EGFR to induce EGFR autophosphorylation at tyrosine1045 and trigger ubiquitination by inducing the formation of EGFR/Cbl complexes, resulting in the degradation of EGFR; however, Cbl-shRNA abolished rLZ-8-induced EGFR degradation. We provide the first evidence showing that rLZ-8 inhibits growth and induces apoptosis of lung cancer cells by promoting EGFR degradation. The current findings therefore suggest a novel anti-cancer function of rLZ-8 that targeting EGFR overexpression or mutation as well as EGFR-dependent processes in cancer cells.
Introduction
Fungal immunoregulatory proteins (FIPs) are small molecule proteins that are purified from various fungi. FIPs possess immunomodulating and anti-tumor activities, [1] [2] [3] suggesting that they may be promising candidates in applications aimed at increasing access to medical care and clinical disease therapies. One FIP, Ling Zhi-8 (LZ-8), was first isolated and cloned from Ganoderma lucidum in 1989. 4 LZ-8 consists of 110 amino acids, and its immunoglobulin-like structure forms non-covalently linked homodimers that have biological activities. 5 LZ-8 has excellent thermal and acid stability, and it shares biological functions similar to other FIPs. We previously demonstrated that recombinant LZ-8 (rLZ-8) effectively prevented lung cancer cell proliferation and metastasis by mediating the activity of the ribosomal protein S7-MDM2-p53 pathway and promoting MDM2-mediated ubiquitination-dependent Slug degradation. 2, 6 However, there remains no evidence show the targeted membrane protein of rLZ-8 on cancer cells. Epidermal growth factor receptor (EGFR), a member of the ErbB family, is an important membrane receptor tyrosine kinase that links extracellular signals to cellular homeostasis. 7 Under normal conditions, EGFR signaling is triggered by the binding of EGFR ligands, including epidermal growth factor (EGF). It is thought that ligand binding induces the homo-or hetero-dimerization and autophosphorylation of EGFR or other EGFR family members, which result in the activation of various downstream signaling cascades, including the Ras/MAPK, PI3K/AKT and STAT pathways. 7, 8 Overexpressing the EGFR protein, inducing a high EGFR gene copy number, and dysregulating the tyrosine kinase activity of mutated EGFR led to aberrant EGFR downstream signaling and promoted tumor cell proliferation, differentiation, survival, invasion and metastasis. 9 Importantly, abnormal EGFR expression has been associated with human cancers, including lung, head and neck, pancreas, colon and brain cancers. EGFR is therefore considered to be a well-validated therapeutic target for cancer treatments. However, clinical responses to EGFR inhibitors and monoclonal antibodies have included serious complications, such as drug resistance and secondary mutation, [10] [11] [12] [13] [14] suggesting that developing novel therapies and synergistic strategies that involve combinations with anti-EGFR therapies would be valuable.
When a ligand binds to EGFR, it induces its internalization and proteasome/lysosomal degradation. 15, 16 The major regulatory mechanisms involved in EGF-induced EGFR degradation depend on endocytosis and ubiquitination. 17 Ubiquitination, a posttranslational modification mechanism, is originally thought to affect proteins by regulating many other cellular processes and responses, including membrane trafficking, endocytosis and degradation, via the 26S proteasome. 18 The activation of EGFR by EGF leads to the autophosphorylation of EGFR tyrosine 1045. This process is accompanied by binding of the ubiquitin E3 ligase, Cbl, which results in the ubiquitination of EGFR. 19 Moreover, Cbl-dependent ubiquitination is required for the recruitment of EGFR into clathrin-coated pits, which is followed by its internalization and endocytosis, 20 and EGF-stimulated EGFR endocytosis can be abolished by knocking down clathrin. 21 In our study, we show that rLZ-8 induces cell cycle arrest and promotes cell apoptosis by downregulating the expression of wild-type and mutated EGFR, resulting in the loss of phosphorylation of EGFR, AKT and ERK1/2. In addition, we show that rLZ-8 triggers the signaling pathway that leads to the degradation of EGFR and promotes the binding of c-Cbl to EGFR, which results in the ubiquitination and degradation of EGFR. These novel findings support our hypotheses that the mechanism by which rLZ-8 induces EGFR degradation is clathrin-mediated and endocytosis-dependent and that it requires c-Cbl-mediated ubiquitination. Here, we provide data that reveals, for the first time, a novel function of rLZ-8, and we discuss how this function might be exploited in new strategies for lung cancer therapies.
Materials and Methods

Cell lines
The human NSCLC adenocarcinoma cell lines A549 and CL1-5 22 were obtained from ATCC: The Global BioResource
Center and Dr. P.C. Yang (NTU, Taipei, Taiwan), respectively. The human NSCLC adenocarcinoma cell lines H1975 and PC9 were obtained from Dr. C.M. Tsai (NYMU and Veteran's General Hospital, Taipei, Taiwan). The human NSCLC squamous cell lines H226 and H520 were obtained from Dr.
M.H. Yang (NYMU, Taiwan) and BioResource Collection and Research Center (BCRC, Hsinchu, Taiwan), respectively. The Lewis lung carcinoma cell line (LLC1) was purchased from BCRC (Hsinchu, Taiwan). All cells were cultured as previously described. 2, 6, 23 Preparation of the recombinant Ling Zhi-8 (rLZ-8) protein
The expression plasmid containing the LZ-8 gene was produced and the purification of his-tagged rLZ-8 proteins was performed as previously described.
24
In vivo LLC1 tumor-bearing mouse model Male C57BL/6 (H-2b; 6-8 weeks old) mice were purchased from the National Laboratory Animal Center (Taipei, Taiwan). Mice were raised under a specific pathogen-free condition in the animal center of NYMU according to the regulations of the Animal Care Committee of NYMU (IACUC Approval No: 1031224). The mice were weighed and randomly distributed into different experimental groups (n 5 5 per group). On Day 0, approximately 2 3 10 5 lung cancer cells were suspended in 100 ll of serum-free DMEM and then subcutaneously (s.c.) implanted into the left flank of each mouse because this location allowed for easy observation and detection. The mice were divided into two groups, and each group contained five animals. Group 1 animals were intraperitoneally injected with PBS and served as controls. The animals in Group 2 were intraperitoneally injected with rLZ8 (7.5 mg/kg). Treatments were administered on days 3, 7, 11 and 15. Tumor size was measured in each mouse using a set of digital callipers, and tumor volumes were calculated using the formula L1 3 L2 3 H, where L1 was the long diameter, L2 was the short diameter, and H was the height of the tumor. The mice were sacrificed on Day 17, and the tumors were then excised, weighed and stored at 2808C until further analysis.
Fluorescence and Confocal Laser Microscopy
Cells were fixed with 4% paraformaldehyde in PBS for 15 min and then permeabilized using 0.1% Triton X-100 (Sigma-Aldrich, MO, USA) for 5 min at room temperature. The samples were blocked in blocking buffer (PBS, 1% BSA) and then incubated with anti-EGFR antibodies and anti-his-tag (rLZ-8) antibodies for 1 hr at room temperature. The cells were then exposed to the corresponding rabbit-FITC secondary antibodies (Santa Cruz Biotechnology) for 30 min at room temperature. Nuclei were counterstained using 4 0 ,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) and observed using an Olympus FV1000 fluorescence microscope.
Immunoprecipitation of EGFR for the in vitro ubiquitination assays
To assess the ubiquitin-regulating ability of rLZ-8 in NSCLC cells, cells were pre-cultured in MG-132 (10 lM) for 30 min to inhibit proteasome activity. This was followed by treating the cells with or without rLZ-8 (10 lg/ml) for 15 min. The cells were then extracted using lysis buffer and centrifuged at 13,000g for 10 min at 48C. The cleared supernatants were then prepared for immunoprecipitation. The cell lysates (400 lg of protein) were immunoprecipitated overnight at 48C using EGFR antibodies (0.5 lg). Protein A/G was added to the immunoprecipitates, which were then incubated at 48C overnight. The beads were collected using centrifugation at 10,000g for 2 min and then washed 5 times in PBS containing protease inhibitors and phosphatase inhibitors. The immunoprecipitated complexes were subjected to SDS-PAGE followed by immunoblotting with anti-ubiquitin antibodies to detect polyubiquitinated EGFR proteins. The results of the in vitro ubiquitination assays were visualized using an enhanced chemiluminescence Western blotting system.
Statistical analysis
All of the data are expressed as the mean 6 standard error. Significant differences between two groups were determined using t-test analyses in Microsoft Excel. A p values of <0.05 was considered to be statistically significant (*p < 0.05, **p < 0.01 and ***p < 0.005).
Please see the Supplementary Methods section for additional methods used in our study.
Results
rLZ-8 suppresses epidermal growth factor receptor (EGFR)-dependent proliferation in NSCLC
To examine the effects of rLZ-8 on lung cancer cell viability and to determine whether rLZ-8-induced suppression of cell proliferation involves EGFR, we selected three wild type (wt) EGFR-expressing (wt-EGFR) cell lines, including A549 and CL1-5 (NSCLC adenocarcinoma cell lines), H226 (NSCLC squamous cell line), two mutated EGFR-expressing cell lines (mut-EGFR), including PC9 (exon 19 deletion) and H1975 (L858R and T790M), and H520 (an NSCLC squamous EGFR-null cell line), which does not express EGFR, for our study. As shown in Figure 1A , we found that rLZ-8 efficiently inhibited cell viability in both the wt-and the mut-EGFR cell lines but not in the H520 cells. To further investigate whether rLZ-8 suppression of cell viability involves EGFR, we overexpressed wt-EGFR in the H520 (wt-EGFR:H520) cells, and we found that EGF induced the phosphorylation of EGFR, AKT and ERK1/2 (data not shown), suggesting that the exogenous expression of wt-EGFR-regulated EGFR downstream signaling pathways. Moreover, we found that rLZ-8 decreased cell viability in wt-EGFR:H520 cells (Fig. 1B) .
To explore the mechanisms of antitumor action of rLZ-8, we further analyzed the effect of rLZ-8 on cell cycle distribution in A549, H1975 and PC9 cells. Comparing to the untreated control cells, we found that rLZ-8 increased the number of A549, H1975 and PC9 cells in the subG1 phase upon 72 hr treatment (Fig. 1C) . Next, we detected the apoptosis of A549, H1975 and PC9 cells which treated with various concentrations of rLZ-8 for 48-72 hr by flow cytometry (Fig. 1D) or immunoblotting of caspase-3 and PARP (Fig.  1E) . We found that rLZ-8 significantly induced cell death through apoptosis in A549, H1975 and PC9 cells.
rLZ-8 inhibits auto-phosphorylation of EGFR and downregulates EGFR expression
Since abnormal EGFR activation and expression are correlated with malignant lung tumor, we next examined the effect of rLZ-8 on the level and activation of EGFR. We treated different types of NSCLC cells with rLZ-8 and found that rLZ-8 significantly suppressed the total protein level of EGFR at 3 hr and 48 hr (Figs. 1E and 2A). rLZ-8 also significantly downregulated EGFR expression in wt-EGFR:H520 cells (Fig.  2B ). Next, we found that rLZ-8 abolished EGFR autophosphorylation at the Y1068 and Y1173 residues at 3 hr (Figs. 2C and 2D) and 24 hr ( Supplementary Fig. S1 ). Moreover, using the EGFR dimerization assay, we found that rLZ-8 did not promote dimerization of EGFR (Fig. 2E) ; whereas, EGF induced formation of EGFR dimmers as previous study. 25 We also examined the effects of rLZ-8 on EGFR downstream signaling pathways. We found that treating NSCLC cells with rLZ-8 reduced the levels of phosphorylated ERK1/2 and AKT ( Fig. 2F ), suggesting that rLZ-8 induced EGFR degradation and inhibited EGFR downstream signaling, resulting in the inhibition of viability in NSCLC cells.
rLZ-8 suppresses tumorigenesis and reduces EGFR protein levels in LLC1 cell-bearing mice in vitro and in vivo
We next examined the anti-tumor activity of rLZ-8 in a lung cancer cell-bearing mouse model in vivo. We first showed that rLZ-8 significantly inhibited cell viability (Fig. 3A) and downregulated EGFR levels in LLC1 cells in a dosedependent manner in vitro (Fig. 3B ). rLZ-8 also abolished the EGF-induced tyrosine phosphorylation of EGFR (Fig.  3C ). Furthermore, using gefitinib and AG1478, we found that blocking EGFR activity significantly inhibited proliferation in LLC1 cells (data not shown), suggesting that rLZ-8-induced EGFR degradation mediates cell viability in these cells. Next, we examined the effect of rLZ-8 in vivo in LLC1-bearing mice. We found that rLZ-8 significantly decreased tumor volume (Figs. 3D and 3E) and tumor weight (Fig. 3F ) in LLC1-bearing mice. In contrast, we observed only a small difference in mouse body weight between the rLZ-8-injected mice and the PBS control groups (Fig. 3G) , similar to the results of our previous study. 2 Using Western blot analysis to analyse the expression of EGFR in the experimentally induced tumor lesions, we found that the rLZ-8-injected LLC1-bearing mice expressed lower levels of EGFR than the control group ( rLZ-8 binds to EGFR to promote its endocytosis
The above-described results show that rLZ-8 significantly suppressed the total protein levels and phosphorylation of EGFR. It has previously been shown that the ligand-induced degradation of EGFR involves EGFR endocytosis. 17 We therefore hypothesized that one means by which rLZ-8 might suppress EGFR is by inducing its endocytosis and degradation.
The effect of rLZ-8 on the cellular distribution of EGFR was analyzed using fluorescence microscopy. Here, using wt-EGFR cells that endogenously express high levels of EGFR (A549 and H226), we found that EGFR was mainly localized on the plasma membrane (Fig. 4A) . Applying rLZ-8 and EGF induced EGFR to distribute more diffusely and to appear as punctate intracellular clusters in the cytoplasm in A549 and and EGF (100 ng/ml) for 3 hr. Total protein extracts were directly immunoblotted using anti-EGFR and anti-pEGFR (Y1068 and Y1173) antibodies, and the results were viewed via Western blot analysis using a-tubulin as an internal control. (E) A549 cells were pre-treated with rLZ-8 (5 lg/ml) or EGF (100 ng/ml) for 5 min and then incubated with BS 3 (bis(sulfosuccinimidyl)suberate, an amine-to-amine crosslinker, Thermo Fisher Scientific, Inc., lL, USA) for 15 min at room temperature. (F) A549, CL1-5, H1975 and PC9 cells were treated with rLZ-8 (10 lg/ml) for 3 hr. Total protein extracts were then isolated and directly immunoblotted using anti-pAKT (S473) and anti-pERk1/2 antibodies, and the proteins were detected using Western blot analysis. AKT, ERK and a-tubulin were used as the internal controls.
H226 cells (Fig. 4A) . Moreover, the binding of EGF to EGFR accelerated EGFR internalization in clathrin-coated pits, which resulted in the degradation of the receptor. 21, 26 To investigate whether rLZ-8-induced EGFR degradation is induced by endocytosis, we performed experiments to deplete the clathrin heavy chain in NSCLC cells. After first confirming the efficacy of two clathrin heavy chain shRNAs, #2755 (sh-S1) and #2757 (sh-S2), we found that clathrin knockdown led to a reduction in the total protein level of clathrin in A549, CL1-5 and H226 cells (Fig. 4B) . Next, we examined whether rLZ-8-induced EGFR degradation is dependent on clathrin-mediated endocytosis in NSCLC cells. We found that clathrin knockdown induced a significant decrease in the turnover of rLZ-8-induced EGFR degradation in NSCLC cells ( Fig. 4C and Supplementary Fig. S2 ). These results suggest that rLZ-8-induced degradation of EGFR involves a clathrinmediated endocytosis pathway.
Because the downregulation of EGFR by rLZ-8 may involve an intracellular pathway similar to the pathway induced by EGF-mediated EGFR endocytosis and degradation, we hypothesized that rLZ-8 may interact with EGFR. Co-localization of rLZ-8 and EGFR was analyzed using fluorescence microscopy, and we found that EGFR and rLZ-8 were mainly co-localized on the plasma membrane and that they formed punctate intracellular clusters in the cytoplasm of A549 and H226 cells (Fig. 4D) . To further examine the association between rLZ-8 and EGFR, immunoprecipitation assays were performed using anti-EGFR and anti-his-tag (for detecting rLZ-8) antibodies. In A549 and H226 cells, rLZ-8 was present in the immunoprecipitates obtained using the anti-EGFR antibody, and EGFR was retrieved using an anti-his-tag antibody via immunoprecipitation (Fig. 4E) . Moreover, we also examined the binding affinity of rLZ-8 for purified EGFR that was immobilized on an ELISA plate, and HEK293T cells were transfected with three types of sh-clathrin and scrambled plasmids to produce lentiviruses. Viruses containing individual clathrin-shRNAs were infected into A549, CL1-5 and H226 cells for 24 hr, and then puromycin selection was performed. Clathrin expression was detected in whole cell lysates using Western blot analysis. (C) A549, CL1-5 and H226 cells (mock and knockdown via sh-clathrin) were incubated with rLZ-8 (5 lg/ml) for 0-12 hr and then subjected to Western blot analysis to detect the expression levels of EGFR and clathrin; a-tubulin was used as the internal control. Numbers indicate densitometry values that were normalized to the relative a-tubulin value. (D) A549 cells and H226 cells were treated with rLZ-8 (10 lg/ml) for 3 hr. The localization of EGFR and rLZ-8 was then examined in immunofluorescence staining assays. The expression patterns of EGFR and rLZ-8 were examined by staining the cells for rLZ-8 with PE (red) and by using anti-EGFR antibodies and DAPI to stain for EGFR (green) and nuclei (blue), respectively. Scale bar: 30 lm. (E) rLZ-8 binding to EGFR was assessed in immunoprecipitation assays using EGFR and His-tag (rLZ-8) antibodies in A549 cells that were treated with rLZ-8 (5 lg/ml) for 30 min. After incubation, whole cell lysates were immunoprecipitated overnight at 48C using anti-EGFR or anti-his-tag antibodies. (F) A549 cells were co-treated with rLZ-8 (10 lg/ml) and EGF (100 ng/ml) for 3 hr. The protein levels of rLZ-8 and EGFR were measured using Western blot analysis. [Color figure can be viewed at wileyonlinelibrary.com] we found that rLZ-8 bound to EGFR in a dose-dependent manner ( Supplementary Fig. S3 ). Furthermore, we found that rLZ-8 enhanced EGF-induced EGFR degradation (Fig. 1F) . These data suggest that rLZ-8 is physically associated with EGFR and that it triggers EGFR-induced endocytosis and degradation.
rLZ-8 induces EGFR degradation via the ubiquitin-proteasome pathway
We found that rLZ-8 can significantly decrease EGFR protein levels within a short period of time. To determine the mechanism by which rLZ-8 decreases EGFR expression, we analyzed the half-life of EGFR in A549, H1975, CL1-5 and H226 cells following treatment with cycloheximide (CHX). Initially, we found that the half-life of EGFR was much longer in NSCLC cells exposed to CHX alone (Fig. 5A) . However, the half-life of EGFR proteins in cells co-treated with rLZ-8 and CHX decreased to 150 min compared to that in cells treated with CHX alone. These results indicate that rLZ-8 performs a unique function that contributes to the acceleration of EGFR degradation in lung cancer cells.
Next, we examined whether rLZ-8-induced EGFR degradation is dependent on proteasome or lysosomal systems. Treatment of cells with a proteasome inhibitor, MG132, recovered rLZ-8-induced EGFR degradation in wt-EGFR and mut-EGFR lung cancer cells (Fig. 5B) , whereas chloroquine, a lysosome inhibitor, failed to rescue rLZ-8 activity in these cells (data not shown). These data suggest that the ubiquitin-proteasome pathway (UPP) is involved in rLZ-8-induced degradation of EGFR. An in vitro ubiquitination activity assay was therefore performed to further explore the mechanism by which rLZ-8 induces EGFR degradation. In these assays, we analyzed ubiquitin proteins to examine the role and involvement of rLZ-8-mediated proteasome ubiquitination in the degradation of EGFR proteins in NSCLC cells. We initially examined endogenously ubiquitylated EGFR in lung cancer cells. As shown in Figure 5C , rLZ-8 enhanced the ubiquitination of EGFR in A549, H1975 and PC9 cells that were pre-treated with MG132. These results indicate that the smeared bands observed in the gels consisted of EGFR proteins that were polyubiquitinated via processes involving UPP during rLZ-8-enhanced EGFR degradation in NSCLC cells.
rLZ-8 induces EGFR degradation signaling and enhances the conjugation of Cbl and EGFR
Our and other previous studies have shown that the EGFinduced phosphorylation of EGFR at tyrosine 1045 (Y1045) leads to binding between EGFR and Cbl and that EGFR ubiquitination results in its proteasome/lysosomal degradation. 27, 28 Here, we hypothesized that rLZ-8 promotes the ubiquitination and degradation of EGFR by activating EGFR degradation signaling. To examine the effects of rLZ-8 on the phosphorylation of EGFR:Y1045, total cell lysates were prepared from A549 and H226 cell cultures and used to detect rLZ-8-induced phosphorylation at EGFR:Y1045 with or without stimulation by EGF. As shown in Figure 6A , we observed that rLZ-8 induced markedly higher levels of EGFR phosphorylation at tyrosine 1045 than were observed in the cells treated with EGF-stimulation alone, and that these increases occurred in a time-dependent manner. We next examined whether Cbl is involved in the processing step of rLZ-8-mediated UPP degradation of EGFR in lung cancer cells. In A549 and H226 cells, treatment with rLZ-8 resulted in a significantly higher amount of c-Cbl being bound to EGFR in the rLZ-8-treated cells than in the control cells (Fig.  6B) . We further analyzed the activation of c-Cbl in lung cancer cells during rLZ-8-induced ubiquitination of EGFR. Not surprisingly, the phosphorylation of c-Cbl was induced by treatment with rLZ-8 (data not shown). These results collectively suggest that Cbl is involved in the rLZ-8-enhanced ubiquitin-dependent degradation of EGFR.
Knockdown of c-Cbl recovers rLZ-8-induced degradation of EGFR
To further determine whether rLZ-8-induced EGFR degradation is Cbl-dependent, we experimentally knocked down cCbl in A549 and H226 cells. We first confirmed the efficiency of c-Cbl knockdown by sh-S1 (#288694) and sh-S2 (#288695). We found (using Western blot analysis) that cCbl knockdown led to a reduction in the overall protein levels of c-Cbl in A549 and H226 cells (Fig. 6C) . We next examined the relationship between Cbl and EGFR in rLZ-8-treated cells. As expected, c-Cbl knockdown significantly reduced the rate of turnover of rLZ-8-induced EGFR degradation in A549 and H226 cells (Figs. 6D) . Moreover, when cells were treated with rLZ-8 for 12 hr, we found that c-Cbl knockdown restored approximately 26% and 17% of all EGFR degradation events in A549 and H226 cells, respectively, compared to the levels observed in scrambled cells (Fig.  6E) . Collectively, these data indicate that c-Cbl is each sufficient to induce rLZ-8-mediated EGFR degradation.
Combinations of cisplatin with rLZ-8 synergistically induce apoptosis and inhibit growth in gefitinib-resistant lung cells
To verify the clinical application of rLZ-8, we next examined the effect of a combined treatment including rLZ-8 and cisplatin on the expression of EGFR and cell viability in gefitinib-resistant lung cancer cells (A549 and H1975) in vitro. As shown in Supplementary Figure S4A , we found that co-treatment with rLZ-8 and cisplatin resulted in a significant decrease in cell viability. A similar phenomenon was observed when cell death was assessed using crystal violet staining and bright-field imaging (Supplementary Fig. S4B ). Moreover, we demonstrated that combined treatment with rLZ-8 and cisplatin resulted in a significantly lower level of EGFR protein than treatment with cisplatin alone (Supplementary Fig. S4C ). Specifically, cisplatin induced the activation of signaling pathways that lead to the DNA damage response, thereby inducing apoptosis. 29 We also examined rLZ-8 induced sensitivity to cisplatin in lung cancer cells. Using Western blot assays, we observed that treating cells with a combination of rLZ-8 and cisplatin induced the activation of caspase 3 in both H1975 and A549 cells (Supplementary Fig. S4C ). We next determined the number of apoptotic cells using flow cytometry, and we found an increase in the proportion of apoptotic cells in the cells that were co-treated with rLZ-8 and cisplatin (Supplementary Fig.  S4D ). These results indicate that a combined treatment that included rLZ-8 and cisplatin significantly promoted apoptosis in H1975 and A549 cells, suggesting that rLZ-8 and cisplatin together are more effective than either treatment alone. Together, these results suggest that rLZ-8 significantly enhances the cisplatin-mediated inhibition of cell growth and induction of apoptosis in gefitinib-resistant lung cancer cells.
Discussion
The EGFR signaling cascade is a pivotal pathway in the development and progression of a wide variety of human cancers.
The majority of patients with lung cancer exhibit abnormal EGFR expression, and the constitutive activity of EGFR in mut-EGFR cell lines has been associated with aberrant EGFR downstream signalling 9 Currently, EGFR TKIs, which efficiently inhibit lung tumorigenesis, are the most widely targeted therapeutic agents in lung cancer research. However, >50% of lung cancer patients develop an acquired resistance to EGFR TKI therapy. 10 In addition, the germ line mutation T790M has been detected in EGFR-mutant tumors. All of these findings indicate that there is a need to develop new strategies and identify new drugs to efficiently treat lung cancer.
Because the dysregulation of activated EGFR is a key pathogenesis in lung cancer, we explored the role of rLZ-8, which is derived from the medicinal mushroom G. lucidum, with the aim of determining its usefulness as a potential therapeutic agent. We performed a series of in vitro analytical approaches using a collection of cancer and EGFR mutant cell Binding between c-Cbl and EGFR was assessed via immunoprecipitation using EGFR antibodies in A549 and H226 cells that were treated with EGF (100 ng/ml) or rLZ-8 (5 lg/ml) for 30 min. After incubation, the whole cell lysates were isolated and immunoprecipitated overnight at 48C using anti-EGFR antibodies. The c-Cbl and EGFR proteins levels were measured using Western blot analysis. (C) HEK293T cells were transfected with sh-c-Cbl or scrambled plasmids to produce lentiviruses. A549 and H226 cells were infected with viruses containing a shRNA for 24 hr and then selected using puromycin. The expression levels of c-Cbl were then detected using Western blot analysis in whole cell lysates. (D) A549 and H226 cells (mock and sh-c-Cbl knockdown) were incubated with rLZ-8 (5 lg/ml for A549 and 10 lg/ml for H226) for 0-12 hr and then submitted to Western blot analysis to detect the expression of EGFR and c-Cbl. a-tubulin was used as the internal control. (E) The results of (D) were quantified using densitometry in ImageJ software, and the densitometric values were normalized against the relative a-tubulin values. The data represent the mean 6 SD. Significant differences between scrambled and sh-c-Cbl, *p <0.05.
lines, and the results provided us with new insight into the mechanisms by which rLZ-8 impacts biological responses in cancer. Here, we showed that the rLZ-8 induced the Cblmediated clathrin-dependent degradation of both wt-and mut-EGFR and also exhibited efficacy against lung cancer cells. In contrast, rLZ-8 did not downregulate other membrane proteins, including transforming growth factor b (TGFb) receptors, fibroblast growth factor receptor (FGFR) and integrin beta 1, but also induced c-Met (hepatocyte growth factor receptor) degradation as previous study 30 (data not shown). Moreover, our unpublished data showed that rLZ-8 also inhibits cell viability and suppresses EGFR expression in various cancer cells, such as breast, head and neck, colon and cervical cancer (Supplementary Fig. S5 ). These data provide us with a substantial basis for deciphering the crucial role of rLZ-8 in the regulation of EGFR expression.
EGF induces EGFR dimerization, which results in the activation of EGFR downstream signaling pathways. 31 However, EGF also stimulates the autophosphorylation of EGFR at residue of Y1045 and induces the conjugation of Cbl and EGFR, resulting in the ubiquitination, endocytosis and degradation of EGFR. 20, 27 Recently, it has been shown that CCN2, a human connective tissue growth factor, and T315, a smallmolecule, stimulate tumor-suppressing signaling pathways by targeting on EGFR and inducing Cbl-mediated EGFR degradation in lung cancer, 32, 33 these data suggest that the activation of EGFR degradation signaling may be a new strategy for approaching lung cancer therapies. Here, using confocal and immunoprecipitation assay, we first demonstrated that the characteristic of rLZ-8 is like the EGF, which could interact with EGFR to induce Cbl-mediated EGFR degradation signaling. Interestingly, we found that rLZ-8 did not induce EGFR dimerization; whereas, EGF significantly promoted EGFR dimerization which activated EGFR and its downstream signaling, AKT and ERK. Moreover, using competitive assay, we found that EGF could enhance the interaction of rLZ-8 and EGFR (data not shown) and accelerate the rLZ-8-induced degradation of EGFR. In contrast, rLZ-8 effectively abolished EGF-induced phosphorylation of EGFR and its downstream signal molecules. In addition, it has known that cetuximab (C225), a EGFR monoclonal antibody, binds to the extracellular domain of EGFR and blocks EGF binding site of EGFR. 34 We also examined the effects of EGFR expression in the combination of cetuximab and rLZ-8. We found that the combined therapy of cetuximab and rLZ-8 synergistically downregulated EGFR expression for the short time treatment (data not shown). Those results suggested that rLZ-8 could interact with EGFR (but it did not bind to EGF binding site of EGFR) on either EGF or serum free condition, leading to induce EGFR degradation signaling. However, the results of multiple sequence alignments did not reveal correlated sequences between LZ-8 and other potentially related EGFR ligands (data not shown). Studying the binding site of rLZ-8 on EGFR is our further work. Our findings show that rLZ-8 acts as a novel ligand for EGFR and that rLZ-8 interacts with EGFR to promote the EGF-induced degradation of EGFR (Supplementary Fig. S6 ).
EGFR mutations are common in lung cancer patients. 9, 10 Although such point mutations can be located anywhere in the EGFR TK domain, approximately 90% of the identified EGFR mutations are deletions in exon 19 or L858R point mutations in exon 21. These EGFR mutations increase the kinase activity of EGFR, which induces the hyperactivation of downstream pro-survival signaling pathways. The use of EGFR TKIs is a validated clinical lung cancer therapy. However, the clinical use of EGFR TKIs can lead to serious problems, such as drug resistance and secondary mutations. This is supported by the occurrence of the EGFR T790M mutation, which is identified as a "second-site mutation" in over half of the EGFR-mutant lung cancers that develop acquired resistance to the EGFR TKIs gefitinib or erlotinib. 35 To the best of our knowledge, this is the first time that the rLZ-8-mediated degradation of EGFR and inhibition of cell viability have been shown to occur in both wt-and mut-EGFRexpressing lung cancer cells. We also examined the anticancer activity of rLZ-8 in EGFR-mut cells, such as PC9
19del , which is a TKI-sensitive line of cells, and H1975
T790M/L858R , a TKI-resistant cell line. Interestingly, our findings reveal that rLZ-8 induces the degradation of mut-EGFR, inhibits EGFR downstream signaling pathways, and suppresses viability in PC9 and H1975 cells. In addition, we found that cotreatment with rLZ-8 and gefitinib resulted in a significant decrease in viability of A549 and H1975 cells, suggesting that rLZ-8 and gefitinib together are more effective than either treatment alone in gefitinib resistant or non-sensitive lung cancer cells (Supplementary Fig. S7 ). Moreover, the chemotherapy (using cisplatin) is the first therapeutic strategy under lung cancer patients without gefitinib sensitive EGFR mutation. Our results indicate that the combined use of cisplatin and rLZ-8 reduced survival and induced apoptosis in TKIresistant A549 and H1975 cells.
In summary, our study provides a model for the study of rLZ-8, which inhibits viability in lung cancer cells by inducing the degradation of EGFR and the activation of Cbl. Moreover, we found that GMI, a immunomodulatory protein from Ganoderma microsporum, also inhibits autophosphorylation of EGFR and induces EGFR degradation (data not shown), suggesting that Ganoderma proteins may play the potential agent for anti-tumor. 36 We offer a paradigm for investigating a novel biological defence signaling mechanism involving a foreign protein that was shown to suppress tumorigenesis. This approach provides a new strategy for suppressing cancer progression.
